by, Martin Bayne, ChangingAging ContributorTweetShareShareEmail0 Shares[Editor’s Note: This post was originally published at The Voice of Aging Boomers]Next week marks my 3,652 day as an assisted living resident – my ten-year anniversary as a member of America’s Institutional Aging Community.Statistically, only 1 in 25,000 residents over 55 survives that long. And when you factor into this equation my Young-Onset Parkinson’s, Congestive Heart Failure and two Pulmonary Embolisms, the odds become astronomical. (My first order of business upon waking every morning is to acknowledge, with gratitude and astonishment, that I actually woke up!)Yet, here I am, after 63 years, still inhaling and exhaling. Still setting my quality-of-life indicator at its highest setting — indicating that despite ravaging tremors, excruciating pain and a failing heart that often makes me fight for each breath, I not only refuse to lay down and die — I still squeeze what joy and inspiration I can from these ten-trillion cells called Martin Bayne.And how do I continue to put one foot in front of the other in this often-disappointing and painful journey I call my life? In a word: purpose.Purpose is the magic elixir that trumps pain, transcends any notion of limitation and opens our minds and hearts to possibility.It is also the single most accurate predictor of joy and fulfillment in an aging population.Which brings me to the reason I wrote this post — to share my anniversary with you in a format of “incremental victories.” To openly share the ten-faceted jewel of knowledge and wisdom I’ve been given in exchange for all the pain and tremors. Guard it well. 1. With stillness, we lay the foundation. When the mind settles, we become clear. 2. With courage, we move forward-despite our fear.An authentic warrior recognizes fear as an ally. 3. With forgiveness, we discover true freedom.One-hundred-years from now, what difference will it make? 4. With insight, we accept the change of life’s seasons. We come, we go. Can you remember the face you had before you were born? 5. With gratitude, we honor our elders. Who determines who is “young” and who is “old?” Why, you, of course. 6. With tenderness, we turn the stream of compassion within. She who has herself as playmate, coach and advisor, is a fortunate woman. 7. With faith, we learn surrender. Give your heart away completely. It will always find its way home, bearing gifts. 8. With mindfulness, we do just this thing, now. Life in the past and future — the cruelest prison of all. 9. With generosity, we make ourselves available to serve. When duality drops away, who is serving and who is being served? 10. With purpose, we acknowledge our mission.Purpose is our map; determination the vehicle. Copyright 2013 Martin BayneRelated PostsTen Things You Need To Know About Assisted LivingMartin Bayne has spent the last ten years as an assisted living facility resident and shares the top 10 things to know before moving in.A Great White WhineI recently had a conversation here about an idea that would simultaneously improve the quality of life for residents while saving the lives of rescue animals.Am I Elderly?Today marks the 11th day of rehab in a Skilled Nursing Facility (SNF), following an acute hospital stay for pneumonia.TweetShareShareEmail0 Shares
May 14 2018In Oregon and Denver, where marijuana is legal for recreational use, activists are now pushing toward a psychedelic frontier: “magic mushrooms.”Groups in both states are sponsoring ballot measures that would eliminate criminal penalties for possession of the mushrooms whose active ingredient, psilocybin, can cause hallucinations, euphoria and changes in perception. They point to research showing that psilocybin might be helpful for people suffering from depression or anxiety.”We don’t want individuals to lose their freedom over something that’s natural and has health benefits,” said Kevin Matthews, the campaign director of Denver for Psilocybin, the group working to decriminalize magic mushrooms in Colorado’s capital.The recent failure of a nationally publicized campaign to decriminalize hallucinogenic mushrooms in California may not portend well for the psilocybin advocates in Oregon and Denver — though their initiatives are more limited than California’s.The proposal in the Golden State would have decriminalized sales and transportation of magic mushrooms, not just possession. The proposed Denver measure would apply only to that city, while in Oregon mushroom use would be allowed only with the approval of a physician and under the supervision of a registered therapist.None of the proposed initiatives envisions fully legalizing psilocybin mushrooms, which would allow the government to regulate and tax sales in a similar fashion to medical and recreational marijuana.In Oregon, advocates face a steep climb to qualify their measure for the ballot, because such statewide initiatives typically require hiring paid signature gatherers, said William Lunch, a political analyst for Oregon Public Broadcasting and a former political science professor at Oregon State University.Still, familiarity with recreational marijuana may have “softened up” voters and opponents of drug decriminalization, he said. Oregon legalized marijuana for recreational use in 2015, Colorado in 2012.The Oregon and Denver activists, echoing Lunch, say they hope voters who already accepted pot would now feel comfortable decriminalizing personal use of magic mushrooms as well.Taking mushrooms can lead to nausea, panic attacks and, rarely, paranoia and psychosis. But they generally are considered safer and less addictive than other illegal street drugs.Even so, Paul Hutson, professor of pharmacy at the University of Wisconsin who has conducted psilocybin research, says he is wary of the drive for decriminalization. Psilocybin isn’t safe for some people — particularly those with paranoia or psychosis, he said.”I reject the idea that that this is a natural progression from medical marijuana,” Hutson said, noting that the safety of pot is much better established. Mushrooms, he added, “are very, very potent medicines that are affecting your mind. In the proper setting, they’re safe, but in an uncontrolled fashion, I have grave concerns.”Even psilocybin advocates share Hutson’s concerns. “It is such a powerful compound. People should take it very seriously when experimenting,” Matthews said.These efforts to legitimize hallucinogenic mushrooms come at a time of renewed interest in the potential mental health benefits of psychedelics, including mushrooms, LSD and MDMA (known as ecstasy). Two small studies published in 2016 by researchers from Johns Hopkins University and New York University found that a single large dose of psilocybin, combined with psychotherapy, helped relieve depression and anxiety in cancer patients.A British company backed by Silicon Valley investor Peter Thiel plans clinical studies in eight European countries to test the use of psilocybin for depression. Other research has examined the effectiveness of psilocybin in treating alcohol and tobacco addiction.Related StoriesResearch sheds light on sun-induced DNA damage and repairHospitals’ decision to transfer kids with mental health emergencies is based on insurance typeGoing teetotal shown to improve women’s mental healthIn California, the campaign to decriminalize psilocybin was always a long shot — even though the famously liberal state legalized possession of recreational marijuana in November 2016 and sales starting this year.California ballot measures typically require nearly 366,000 signatures to qualify, and supporters usually have to spend between $1 million and $2 million to pay signature gatherers. A Monterey County couple leading the decriminalization campaign managed to collect more than 90,000 signatures for their proposal with the help of volunteers, but they halted their efforts late last month.The initiative would have exempted Californians 21 and over from criminal penalties for possessing, selling, transporting or cultivating psilocybin mushrooms.Possessing them is generally a misdemeanor under California law, but selling them is a felony. State statistics on psilocybin offenses are scarce, but few people are jailed for such crimes, according to an analysis by the California attorney general’s office.”It’s not a reckless community,” said Kitty Merchant of Marina, Calif., who spearheaded the California psilocybin campaign alongside her husband, Kevin Saunders. “It’s experimentation with your mind and your thoughts. There’s a safeness to it. And there’s an intelligence to it.”Merchant said she and Saunders, both medical marijuana advocates, spent about $20,000 of their own money on the campaign.In Denver, Matthews and his pro-psilocybin colleagues want voters to pass a city ordinance eliminating criminal penalties for possessing, using or growing magic mushrooms. City officials have cleared the measure for signature gathering. Supporters need 5,000 signatures to get it on the ballot in November. Matthews said he has already lined up dozens of volunteer signature gatherers.He said he has used mushrooms to help alleviate depression and other mental health problems. A big part of the decriminalization campaign, he said, is promoting responsible use.Denver, a progressive city in a state that was the first to legalize recreational marijuana, “is a good testing place for this initiative nationwide,” Matthews said. Just getting it on the ballot, whether or not it passes, would be “a huge victory,” he added.In Oregon, activists are proposing a measure for the 2020 ballot that would decriminalize psilocybin statewide for adults 21 and over who get approval from their doctors and agree to participate in a “psilocybin service.” The service would include a preparatory meeting with a therapist, one session of supervised mushroom use and a follow-up visit. Patients would be under the care of state-certified “Psilocybin Service Facilitators.”Tom Eckert, a Portland, Ore.-based therapist who leads the psilocybin decriminalization campaign with his wife, Sheri, said the proposed limitations on psilocybin use are important.”Psilocybin is generally safe, but it puts you in a vulnerable state of mind,” he said. “If you do it in the wrong setting, things can go sideways.”This story was produced by Kaiser Health News, which publishes California Healthline, a service of the California Health Care Foundation. This article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.
Source:https://today.uic.edu/what-can-the-herpesvirus-teach-us-about-oral-inflammation Aug 2 2018A $2 million grant from the National Institutes of Health will help University of Illinois at Chicago researchers study how herpesviruses, and their underlying molecular mechanisms, contribute to increased inflammation in oral diseases, like periodontitis.The researchers, led by the UIC College of Dentistry’s Afsar Naqvi, will also study how manipulating the small molecules that help to regulate gene expression in the herpesvirus may aid health care professionals to diagnose and treat oral diseases.”Herpesviruses are unique in both their lifelong persistence in the human body and in their ability to encode viral microRNAs that not only alter their own genetic activities but their host cells’ functions as well,” said Naqvi, assistant professor of periodontics.Related StoriesNew drug provides hope for patients with Duchenne muscular dystrophyStudy shows potential culprit behind LupusComplement system shown to remove dead cells in retinitis pigmentosa, contradicting previous researchMicroRNAs are small molecules in cells that help to control how genes are expressed.”Herpesvirus encoded microRNA helps the virus to survive in multiple ways,” Naqvi said. “Because we see a correlation between herpesviruses and oral inflammation, we want to examine if viral microRNAs accumulate in inflamed oral tissues and if they impair the body’s immune responses.”Naqvi and his team will study the impact of the five most common herpesviruses associated with oral inflammatory diseases and quantify their microRNA and genome levels.”We want to identify the microRNAs that change when the tissue around the teeth becomes inflamed,” Naqvi said.The funding, which was awarded in July, will support this research for five years, during which time the researchers hope to uncover whether or not viral microRNA can be used as a biomarker to identify patients who may be more prone to oral inflammation and influence treatment decisions toward better outcomes. The research team will also investigate the molecular and cellular mechanisms through which disease-associated herpesvirus microRNAs dysregulate host immune cell functions.”Understanding the way herpesvirus microRNAs affect oral inflammation may also help us develop better therapies and drug targets for common inflammatory conditions, not limited to those in the mouth, like periodontitis,” Naqvi said.Working with Naqvi on this research are UIC’s Deepak Shukla, the Marion H. Schenk Esq. Professor of Ophthalmology, and Salvador Nares, associate professor and head of periodontics research.
Aug 22 2018BrainsWay Ltd., the parent company of BrainsWay USA, Inc., and a global leader in the advanced non-invasive treatment of brain disorders, today announces that it has received De Novo clearance from the U.S. Food and Drug Administration (FDA) for its deep transcranial magnetic stimulation (Deep TMS) system for the treatment of obsessive-compulsive disorder (OCD) in adults.This clearance represents the first ever non-invasive medical device clearance for the treatment of OCD, and the second indication granted for BrainsWay Deep TMS, which was cleared in 2013 for the treatment of treatment-resistant major depressive disorder (MDD). BrainsWay intends to start installing BrainsWay OCD immediately as an upgrade of its current systems and as part of new installations. Clinics that have or will have a Deep TMS systems can now treat MDD and OCD patients.“With the clearance of our BrainsWay OCD device, we are now able to provide an effective and safe treatment option for U.S. patients who are suffering from OCD,” said Yaacov Michlin, president and chief executive officer of BrainsWay. “With more than two million U.S. adults suffering from OCD, this clearance provides us with a significant market opportunity. Importantly, this clearance further establishes Deep TMS as a platform technology that will provide treatments for additional psychiatric indications, subject to successful completion of our currently ongoing multi center studies and regulatory approvals.”BrainsWay’s Deep TMS technology differs from that of other focal TMS devices as it has broad applicability and can directly stimulate areas of the brain at a greater depth and breadth than any other TMS device on the market safely and efficiently. While other focal TMS devices are limited to treating MDD, BrainsWay can now directly target previously unreachable areas of the brain with its proprietary H7-coil, allowing it to effectively treat OCD as well.Dr. Joseph Zohar, professor of psychiatry at the Sackler Faculty of Medicine at Tel Aviv University, chair, International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) and principal pivotal trial investigator, added: Source:https://www.brainsway-global.com/ Prof. Abraham Zangen, a scientific founder and a neurobiological consultant for BrainsWay said: The brain region targeted with the BrainsWay H7- coil is the anterior cingulate cortex, a region known for many years to be centrally implicated in the pathophysiology of OCD. This Deep TMS H7-coil is different from the BrainsWay H1-coil used for treating depression that targets primarily the lateral pre-frontal cortex. The modulation of the anterior cingulate cortex induced by BrainsWay’s special H7- coil, combined with the individualized provocation procedure in addition to the continued pharmacological or psychological treatment, will allow effective treatment for millions of OCD patients.” The clearance of BrainsWay’s OCD device marks a historic milestone in the treatment of this neurological disorder. This is a new groundbreaking treatment option for patients looking for a meaningful and potentially life-changing solution for OCD.”
Reviewed by James Ives, M.Psych. (Editor)Sep 24 2018Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced that the China National Medical Products Administration (NMPA) approved the kinase inhibitor LENVIMA (lenvatinib) as a single agent for the treatment of patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. In China, the application of LENVIMA was submitted in October 2017, and was designated for Priority Review by the NMPA due to LENVIMA’s significant clinical benefit compared to existing treatments, leading to approval in approximately 10 months. This approval marks the first for LENVIMA in China, where the incidence of HCC is high,(1) and the first new systemic therapy approved for the first-line treatment of unresectable HCC in China in ten years.(1)The approval was based on results from the REFLECT study (Study 304),(2) an open-label, Phase 3 trial where LENVIMA demonstrated a treatment effect on overall survival (OS)(1) by statistical confirmation of non-inferiority when compared with the standard of care, sorafenib, in 954 patients with previously untreated unresectable HCC. LENVIMA demonstrated statistically significant superiority and clinically meaningful improvements in progression-free survival (PFS)(2), time to progression (TTP)(3) and objective response rate (ORR)(4). In a subpopulation analysis of 288 patients in the study from the greater Chinese region (mainland China, Hong Kong and Taiwan), LENVIMA demonstrated efficacy based on non-inferiority of OS compared to sorafenib, with improvements also observed in PFS, TTP and ORR3. Approximately 80% of patients in the subpopulation were living with HCC resulting from chronic hepatitis B virus (HBV), which has high unmet medical need. For these patients, LENVIMA demonstrated non-inferiority based on OS compared with sorafenib, thereby demonstrating the effect of LENVIMA in patients with HCC resulting from HBV.Related StoriesBacteria in the birth canal linked to lower risk of ovarian cancerLiver fat biomarker levels linked with metabolic health benefits of exercise, study findsCancer killing capability of lesser-known immune cells identifiedIn the China package insert, the five most common adverse reactions observed in patients treated with LENVIMA were hypertension (45%), fatigue (44%), diarrhea (39%), decreased appetite (34%) and decreased weight (31%), which is consistent with the known side-effect profile of LENVIMA.Liver cancer is the second leading cause of cancer-related deaths and is estimated to be responsible for approximately 750,000 deaths per year globally. Additionally, approximately 780,000 cases are newly diagnosed each year, about 80% of which occur in Asian regions. Specifically, in China, there are approximately 395,000 new cases and 380,000 deaths per year, accounting for approximately 50% of cases worldwide.(1) HCC accounts for 85% to 90% of primary liver cancer cases. Unresectable HCC, for which treatment options are limited, is extremely difficult to treat, and the development of new treatments is necessary.Since the initial launch, more than 10,000 patients have been treated with LENVIMA. Today, LENVIMA is approved as a treatment for refractory thyroid cancer in over 50 countries including the United States, Japan, in Europe and Asia, and as combination with everolimus as a second-line treatment for renal cell carcinoma (RCC) in over 45 countries including the United States and in Europe. For HCC, LENVIMA was approved for use in Japan in March 2018, and in the United States and Europe in August 2018. In Japan, approximately 3,000 HCC patients have been treated with LENVIMA since approval of this indication.Source: https://www.eisai.com/news/2018/news201877.html
ShareTweetSharePinNoreen John. Photo credit: Sun newspaperDominica woke up to the sad news this morning that lawyer, Noreen John has passed away.A family member confirmed to a DNO source this morning that John died in Antigua on her way to London where she was going to seek medical attention.It was recently announced that John would be the United Workers Party’s (UWP) candidate for Grand Bay in the next general election.She was absent when the UWP presented its full slate of candidates at a public meeting on the Dame Eugenia Charles Boulevard on Sunday May 19, 2019.UWP leader Lennox Linton said at the event that John was not well and had left Dominica to seek medical attention overseas.
Post Comment(s) Related News Inter-state gang hiding in sarpanchs house arrested Undertrials death sparks protests in Bathinda Sunil was running a chemist shop in Maur Mandi, which was in name of one Narayan Das. The shop’s licence however had expired in 2018, said IG (Bathinda range) M M Farooqi.He added that Sunil had been sentenced to 10 years’ in prison in May 2011 in the NDPS case and was out on bail. Moreover, there were seven other cases pending against him.On Wednesday night, police seized the stock which was being brought from Ludhiana. Police said Sunil was arrested Thursday. He will be produced in court Friday and police remand will be sought so as to get information about suppliers. FIR against chit fund company in Bathinda Police said Sunil was arrested Thursday.Bathinda Police on Wednesday night seized 10.67 lakh tablets from Maur resident Sunil Kumar, who is out on bail in a case lodged under the Narcotic Drugs and Psychotropic Substances (NDPS) Act. Advertising By Express News Service |Ludhiana | Published: July 12, 2019 8:23:12 am
Varicella zoster virus or varicella-zoster virus (VZV) is one of eight herpesviruses known to infect humans and vertebrates. 3D illustration Credit: Tatiana Shepeleva / Shutterstock The authors write, “During spaceflight there is a rise in secretion of stress hormones like cortisol and adrenaline, which are known to suppress the immune system.” The study adds, “In keeping with this, we find that astronaut’s immune cells – particularly those that normally suppress and eliminate viruses – become less effective during spaceflight and sometimes for up to 60 days after.” The agency a small number of astronauts have developed symptoms of reawakening of the dormant chicken pox virus called herpes zoster or shingles. In long space flight missions this activated virus could be troublesome they add. Shingles is a painful reactivation of the chicken pox virus in a person who has been previously infected with it. This leads to painful blister like lesions along the course of a nerve – usually seen across the face, forehead or along one side of the trunk.The virus remains dormant in the nerves of the person who has had chicken pox for life. It gets activated when there is a Dr Satish Mehta, senior author and an academic at the Johnson Space Centre in a statement said, “NASA astronauts endure weeks or even months exposed to microgravity and cosmic radiation – not to mention the extreme G forces of take-off and re-entry. This physical challenge is compounded by more familiar stressors like social separation, confinement and an altered sleep-wake cycle.”The researchers explain that the NASA keeps a close watch on the physiological effects of space flights on astronaut’s bodies. They do this by monitoring the saliva, blood and urine of the astronauts all along the flight. By Dr. Ananya Mandal, MDMar 19 2019NASA has come up with a warning about herpes zoster or shingles being activated among crew aboard the Space Shuttle and the International Space Station missions. The problem was highlighted in a study that appeared in the latest issue of the journal Frontiers in Microbiology. Related StoriesThe immune system in women may be different from men finds studyPhoseon exhibits KeyPro KP100 UV LED instrument for virus inactivation at World Vaccine CongressCommon cold virus strain could be a breakthrough in bladder cancer treatmentThe team explains that because of the suppression of the immune system the bodies of the astronauts cannot keep the dormant viruses down and thus these are activated. Dr Mehta said, “To date, 47 out of 89 (53%) astronauts on short space shuttle flights, and 14 out of 23 (61%) on longer ISS missions shed herpes viruses in their saliva or urine samples. These frequencies – as well as the quantity – of viral shedding are markedly higher than in samples from before or after flight, or from matched healthy controls.” Dr Mehta said, “Only six astronauts developed any symptoms due to viral reactivation…All were minor.”Longer flights seem to be reactivating the viruses more said the researchers. “The magnitude, frequency and duration of viral shedding all increase with length of spaceflight,” Mehta said. Source:https://www.frontiersin.org/articles/10.3389/fmicb.2019.00016/full